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Purpose: Evaluation of dose escalated salvage radiotherapy (SRT) in patients after radical prostatectomy (RP) who
had never received antihormonal therapy. To investigate prognostic factors of the outcome of SRT and to analyze
which patient subsets benefit most from dose escalation.
Materials and methods: Between 2002 and 2008, 76 patients were treated in three different dose-groups: an
earlier cohort treated with 66 Gy irrespective of pre-RT-characteristics and two later cohorts treated with 70 Gy or
75 Gy depending on pre-RT-characteristics. Biochemical-relapse-free-survival (bRFS), clinical-relapse-free-survival
(cRFS) and late toxicity were evaluated.
Results: Four-year bRFS and cRFS were 62.5% and 85%. Gleason score <8, positive surgical resection margin (PSRM)
and low PSA (≤0.5 ng/ml) before SRT resulted in higher bRFS. Analysis of the whole group showed no clear
dose-outcome relationship. Patients with PSRM, however, had improved bRFS when escalating >66 Gy. While >
70 Gy did not improve the overall results, 4-year bRFS for patients with manifest local recurrence in the high-dose group
was still comparable to those without manifest local recurrences. No grade 4 and minimal grade 3 gastrointestinal and
urinary toxicity were observed.
Conclusions: Dose-escalated SRT achieves high biochemical control. The data strongly support the application of at
least 70 Gy rather than 66 Gy. They do not prove positive effects of doses >70 Gy but do not disprove them as these
doses were only applied to an unfavorable patients selection.
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Radical prostatectomy (RP) is an effective and widely
employed curative treatment for localized prostate can-
cer. Despite that, biochemical relapse after RP will occur
in 17–64% of the patients depending upon the selection
criteria used, and up to a third of these patients will clin-
ically progress to develop metastatic disease and ultim-
ately die of prostate cancer [1].* Correspondence: mohamed.shelan@googlemail.com; Frank.Lohr@umm.de
1Department of Radiation Oncology, University Medical Center Mannheim,
University of Heidelberg, Mannheim, Germany
Full list of author information is available at the end of the article
© 2013 Shelan et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orSerum prostate-specific antigen (PSA) level after RP is
a sensitive marker for tumor persistence and precedes
clinical failure by years before the location of the recur-
rence becomes clinically evident [2]. Postoperative and/
or salvage radiotherapy (SRT) offer a potentially curative
treatment for selected patients with biochemical or local
failure after RP and could reduce the risk of initial fail-
ure in high-risk patients [3,4]. The extent of postopera-
tive and salvage radiotherapy and its most useful timing
are frequently debated issues, with the line of separation
between these two paradigms being increasingly blurred
due to the advent of sensitive PSA-assays [5,6].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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doses have not been defined. In the consensus state-
ments on radiation therapy of prostate cancer, the
American Society of Radiation Oncology (ASTRO) rec-
ommended a dose of “64 Gy or slightly higher”. In ana-
logy to the treatment of primary tumors, delivering
higher doses of radiotherapy to the prostatic bed without
increasing morbidity became a possibility with the devel-
opment of new radiotherapy techniques in the last few
years. The impact of dose escalation in this situation is,
however, not yet clear.
In this retrospective analysis, we evaluated the effect
of dose-escalation on biochemical control in patients
primarily treated with salvage intention radiotherapy)
who had never received hormonal therapy prior to sal-
vage RT. Further analysis aimed to evaluate the different
prognostic factors related to the success of SRT and late
treatment side effects of high dose salvage RT.
Methods and materials
Patient population
We evaluated the patients referred to Department of Radi-
ation Oncology, University Medical Center Mannheim, to
receive SRT after RP between 2002 and 2008. Analysis of
the medical records was performed after approval by the
ethics committee of the Medical Faculty Mannheim,
University of Heidelberg. We reviewed the pre- and post-
operative medical records, including surgical reports,
pathology results, follow-up PSA values and the reported
late toxicities.
Patient characteristics
To study the efficacy of SRT alone without the influence
of confounding therapies in a patient population without
clinically overt metastases, we excluded the patients who
had evidence of lymph node or distant metastasis (more
than 80% of patients had a lymphadenectomy at primary
surgery and are therefore pN0) and those who received
any form of hormonal therapy either before or conco-
mitantly with radiotherapy or after RT without docu-
mented PSA progression. Seventy six patients were
included in this analysis.
Treatment characteristics
Three different patient cohorts have to be looked at sep-
arately. Between 2002 and 2005, patients were treated
with a 3D conformal technique with a dose of 66 Gy re-
gardless of the risk factors (Group A). After this era the
treatment concept was modified, identifying two patient
strata: Patients who failed to achieve postoperative nadir
(PSA nadir < 0.1 ng/ml) or had evidence of postoperative
biochemical failure after RP (PSA rise above 0.2 ng/ ml)
received a dose between 66 and 70 Gy (Group B). Pa-
tients who had positive resection margins and those whohad radiological or histological evidence of local recur-
rence received a dose ≥ 70 Gy (typically ~75 Gy, ~15 Gy
of which were applied in single doses of ~3 Gy as a
hypofractionated boost to the volume with the highest
presumed tumor cell density, Group C). A deviation
from this approach occurred in two instances only: Two
patients who had evidence of manifest local recurrence
were treated nevertheless within group B at the respon-
sible physician’s discretion.
Clinical target volume (CTV) included the prostate
bed, the bladder neck, the urethral anastomosis and the
seminal vesicle bed. The planning target volume (PTV)
included the CTV with a margin of approximately
0.8 cm in all directions. Salvage RT was delivered using
photon beams using 3D-conformal RT exclusively in
34% and a combination of 3D-conformal and Intensity
modulated radiotherapy technique (IMRT) in 66%. The
median radiation dose for all patients was 70 Gy (Range
66–75 Gy). Median dose was 66 Gy (Range 66–66) in
group A, 69.1 Gy (Range 68–69.9 Gy) in Group B and
74.3 Gy (Range 70–75 Gy) in group C.
Statistical analysis
A second biochemical PSA relapse after SRT was de-
fined as a single PSA value >0.2 ng/ml higher than the
post-radiotherapy nadir. Clinical progression was defined
as the occurrence of a local relapse, lymph node metas-
tasis or haematogenous metastasis.
Biochemical relapse free survival (bRFS) was calculated
from the date of start of SRT until biochemical relapse
or death. Clinical relapse free survival (cRFS) was calcu-
lated from the date of start of SRT to the date of clinical
progression or death. The Kaplan-Meier method was
used to estimate bRFS and cRFS. Univariate (log-rank)
analysis was used to test the predictive value of patient-,
tumor- and treatment-related factors on the bRFS. The
p-value was considered significant for p ≤ 0.05.
Toxicity
Any persisting chronic or late toxicities were considered
after 6 months from the end of radiotherapy till the date
of last follow up. All the data were tabulated and scored
according to the LENT-SOMA toxicity scale.
Results
Of 76 patients included in this analysis, 68 patients re-
ceived SRT for rising PSA after RP (minimal time be-
tween RP and SRT: 4 months) and 8 patients were
irradiated based on a positive surgical resection margin
(PSRM) situation with either detectable or even rising
PSA after surgery (minimal time between RP and SRT:
2 months). The patient- and tumor characteristics are
summarized in Table 1.
Table 1 Patient and tumor characteristics
Group A Group B Group C Total
Factor 66 Gy > 66 Gy < 70 Gy ≥ 70 Gy
n =23 (%) n = 15 (%) n = 38 (%) N = 76 (%)
Age:
< 60 years 10(43.5) 4(26.7) 10(26.3) 24(31.6)
≥ 60 years 13(56.5) 11(73.3) 28(73.7) 52(68.4)
Median 63
Preoperative PSA:
≤ 10 ng/ml 10(43.5) 9(60) 22(57.9) 41(53.9)
>10 ng/ml≤ 20 ng/ml 7(30.4) 4(26.7) 10(26.3) 21(27.7)
> 20 ng/ml 2(8.7) 0(0) 4(10.5) 6(7.9)
Missing 4(17.4) 2(13.3) 2(5.3) 8(10.5)
Median 7,9
Tumor size:
pT2 8(34.8) 9(60) 19(50) 36(47.3)
pT3a 8(34.8) 3(20) 12(31.6) 23(30.3)
pT3b 6(26.1) 3(20) 7(18.4) 16(21.1)
Missing 1(4.3) 0(0) 0(0) 1(1.3)
Gleason score:
≤ 6 4(17.4) 1(6.7) 2(5.3) 7(9.2)
7 13(56.6) 9(60) 23(60.5) 45(59.2)
≥ 8 5(21.7) 5(33.3) 13(34.2) 23(30.3)
Missing 1(4.3) 0(0) 0(0) 1(1.3)
Surgical margin:
R1 9(39.1) 5(33.3) 17(44.7) 31(40.7)
Rx (close) 4(17.4) 3(20) 9(23.7) 16(21.1)
R0 8(34.8) 7(46.7) 10(26.3) 25(32.9)
Missing 2(8.7) 0(0) 2(5.3) 4(5.3)
Risk groups:
High 17(73.9) 13(86.7) 33(86.8) 63(82.9)
Intermediate 6(26.1) 2(13.3) 5(13.2) 13(17.1)
Pre-irradiation PSA:
≤ 0.5 ng/ml 15(65.2) 9(60) 22(57.9) 46(60.5)
> 0.5 ng/ml 8(34.8) 6(40) 16(42.1) 30(39.5)
Median 0,5
Evidence of local recurrence
Yes 2(8.7) 2(13.3) 17(44.7) 21(27.6)
No 21(91.3) 13(86.7) 21(55.3) 55(72.4)
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11 patients were dead upon analysis. Only five patients
were known to have evidence of distant metastasis at the
time of death. Median follow-up after SRT was 52 months.
Thirty one patients had a biochemical relapse and 13 pa-
tients developed distant metastases resulting in a 4 year
bRFS of 62.5% (Figure 1) and a 4 year cRFS of 85%.Upon univariate analysis a Gleason score of less than 8
(p = 0.039), a PSRM (p = 0.04) (Figure 2a) and a low PSA
level (≤0.5 ng/ml) before SRT (p = 0.043) (Figure 2b)
were associated with a significantly better bRFS
(Table 2).
When analyzing the whole patient pool, there was no
clear relationship between biochemical outcome and
Figure 1 Kaplan-Meier curve for the biochemical relapse free survival (bRFS).
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ive stratification of dose based on perceived amount of
tumor load for the patients treated later in the series,
there were two cohorts that were sequentially compar-
able: patients with a positive resection margin in group
B had higher bRFS than in group A (100% vs, 66.7%).
bRFS for patients with positive resection margins in
Group C (75.5%, the majority of which had manifestFigure 2 Kaplan-Meier curves for the effect of resection margin staturecurrence and therefore constituted a less favorable se-
lection than those in group B) was lower than for those
in group B but still higher than for those in group A
(Figure 3a) therefore still suggesting a dose-effect rela-
tionship. In Group C, 4 year bRFS for the patients with
manifest local recurrence was still comparable to bRFS
for those who had no evidence of local recurrence
(51.8% vs 52.4%).s on bRFS (a) and pre-irradiation PSA value on bRFS (b).
Table 2 Results of univariate analysis
Factor 48 months bRFS% p-value
Tumor size T2 71 0.2
T3, T4 54
Gleason score ≤ 7 70 0.039
> 7 44.2
Initial PSA ≤ 10 60 0.4
>10-20 73.2
>20 25
Resection margin R0 + Rx 55.8 0.04
R1 77
Local recurrence Yes 61 0.2
No 63
Pre-radiation PSA ≤ 0.5 70 0.043
> 0.5 51
Dose = 66 Gy 63.6 0.1
> 66 Gy < 70 Gy 85.7
≥70 Gy 52.5
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When classified according to LENT-SOMA, at the time
of last follow up no grade 4 late urinary tract complica-
tions were reported. Grade 3 late urinary tract complica-
tions were observed in 3 patients who received a dose
higher than 70 Gy and suffered from increased fre-
quency. No Grade 3 or 4 late gastrointestinal complica-
tions were observed.
Postoperative/pre-RT incontinence could not be assessed
with certainty, therefore late incontinence was not assessed
systematically. Figure 4 shows the incidence of reportedFigure 3 Kaplan-Meier curves for the bRFS for PSRM patients in the d
of local recurrence in the group C (b).late Urinary and Gastrointestinal complications in relation
to the dose group.
Discussion
The best treatment strategy for patients with a rise in
postoperative PSA is still controversial. Salvage RT re-
mains the only therapeutic option that offers a chance of
cure in this situation [7]. Current diagnostic tools do not
accurately identify the site of very early tumor recur-
rence. What is also unclear to date is the appropriate
dose prescription, with current reports being in a corri-
dor between 60 Gy and doses similar to what is applied
in primary radical radiotherapy in excess of 70 Gy.
Several retrospective studies evaluated the efficacy of
SRT in achieving biochemical control after post-RP re-
lapse. Actuarial 5-year-bRFS rates range from 10% to 66%
but methodologically it is difficult to compare between
studies. Different prognostic factors related to a lower
bRFS included: higher Gleason score, capsular or seminal
vesicle extension, free-surgical margins, short PSA-
doubling time and high pre-radiotherapy PSA level [8-10].
However, the previously mentioned factors were not con-
sistently reported or correlated with treatment outcome
among published studies. Pre-radiotherapy PSA level is
the most consistent variable predicting bRFS. The largest
analysis focusing on prognostic factors following SRT was
a multi-institutional, retrospective cohort of 1540 patients
who were treated with SRT between 1987 and 2005 with a
median follow up of 53 months excluding patients who re-
ceived additional hormonal therapy. The overall 6-year
progression-free probability was 32%. When, however, pa-
tients were treated at serum PSA levels of less than
0.5 ng/ml, the progression-free survival probability wasifferent dose groups (a) and patients with and without evidence
Figure 4 The incidence of reported late urinary (4a) and gastrointestinal (4b) complications based on LENT SOMA toxicity scale in
relation to the dose group (A: 66 Gy, B: >66 <70 Gy, C: ≥ 70 Gy).≥ 70 Gy).
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PSA level was greater than 1.5 ng/ml [8]. In another retro-
spective analysis of 635 patients, prostate cancer–specific
and overall survival were significantly improved in patients
who received SRT within 2 years of biochemical recur-
rence among men with a PSA doubling time of less than
6 months, independent of other prognostic features such
as pathological stage or Gleason score [11].
Although PSRM at RP have been demonstrated to be
an important predictor of disease recurrence [12], they
have also been associated with improved bRFS after SRT,
with a patient with positive margins who relapses being
more likely to benefit from SRT targeting the pelvic/
prostate-bed tissues than a patient with negative mar-
gins, whose PSA failure possibly represents distant dis-
ease [10,13].
In our series, a Gleason Score ≤7, a positive resection
margin (R1) and pre-radiotherapy PSA level ≤0.5 ng/ml
were the most important factors related significantly to a
higher biochemical control for the whole cohort. In the
individual dose strata the previous factors, except for the
resection margin status, did not result in a significant
difference in bRFS which was not expected due to the
small numbers in every dose group.
A relevant issue is the question of the appropriate
treatment dose. The advent of IMRT and Image-guided
radiation therapy (IGRT) has rendered the application of
doses in the range of what is being applied in definitive
radiotherapy of prostate cancer possible.
In 1999, the American Society of Radiation Oncology
(ASTRO) recommended a dose of “64 Gy or slightly
higher” for SRT. The European Association of Urology
(EAU) guidelines also recommend a dose between 64–66 Gy. Most of the published series using doses <66 Gy
resulted in 5 years bRFS of less than 50% [9,14-16].
Further dose escalation in SRT above 66 Gy has been
retrospectively analyzed with evidence of significantly im-
proved bRFS [17]. King et al. published the results of a
retrospective study comparing the outcome of 38 patients
treated with 60 Gy and 84 patients treated with 70 Gy
[15]. The results showed a significantly improved 5-year
bRFS from 25% to 58% with the higher dose of 70 Gy. An-
other dose response analysis for SRT by Bernard et al.
showed that doses greater than 66.6 Gy produced a clear
reduction in biochemical failure [14].
Another recent analysis by Siegmann et al. showed
that patients with decreasing PSA during SRT after RP
had excellent outcome after receiving 70.2 Gy with low
toxicity. In retrospect, the results were better than
achieved in a cohort that, irrespective of response, was
treated with 66.6 Gy. While a superiority of 70 Gy over
66 Gy can not be postulated based on these data because
of the selection bias inherent to the selection process for
dose escalation, these data nevertheless confirm the po-
tential of SRT in patients with localized, radiosensitive
disease [13,18].
While our series did not allow the analysis of a possible
dose-effect relationship across the whole patient pool due
to risk-based treatment stratification for the patients treated
later in the series, the results for the sequentially compar-
able cohorts with similar risk treated at different dose levels
suggests that a dose of 66 Gy is not sufficient but at least
70 Gy should be aimed for. This confirms an analysis pub-
lished by Tomita et al. [6] who reported good efficacy of
only 60 Gy in patients with a low PSA (<0.5 ng/ml) at
SRT, but who, nevertheless, see a dose–response effect of
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data suggest that “salvage RT at doses higher than 60 Gy
may improve biochemical outcome even in patients with a
pre-RT PSA value ≤0.5 ng/ml”. An effect beyond 70 Gy
could not be proven in our series with a significant num-
ber of patients with a PSA > 0.5 ng/ml because patients
treated with these doses had an overall unfavorable risk
profile. The results for these patients are inferior to those
in the 70 Gy Group but still good given that most of these
patients had manifest tumor relapse while those others
did not. A dose-effect relationship for such patients be-
yond 70 Gy can therefore not be excluded.
The study by Ohri et al. published in 2012 showed that
the biochemical control rates following SRT increase
with SRT dose and decrease with high pre-SRT PSA
values [19]. It was also reported that severe late GI and
GU toxicity rates increase with SRT dose [19]. In our
analysis based on the LENT SOMA scale the reported
toxicity was minor in all dose groups, most likely reflect-
ing the improved treatment techniques during the
course of dose escalation. Randomized trials such as
SAKK 09/10 are needed to finally decide if dose escal-
ation is beneficial and in which patient strata.
Addition of hormonal treatment may eventually in-
crease the risk of bias in the reported results of SRT, so,
it is important to emphasize that the patients in our
study had never been exposed to hormonal treatment
before or after surgery or concomitantly with radiation.
The benefit of adding hormone therapy to SRT has been
examined in some retrospective studies [20]. The initial
results of the phase III clinical trial (RTOG-9601) pub-
lished in abstract form, comparing RT (64.8 Gy) with RT
plus 2 years of high dose bicalutamide (150 mg per day)
showed that addition of the hormone treatment during
and after RT significantly improved the freedom from
PSA progression and reduced the incidence of distant
metastasis [21]. The final results of this trial are still
pending.
Conclusion
Our study suggests that a biochemical control rate of
62.5% in at 48 months can be achieved with SRT using a
dose ≥ 66 Gy without addition of androgen suppressing
therapy. Pre-radiotherapy PSA level remains an important
prognostic factor for the rate of biochemical control. As in
most series, a positive resection margin is associated with
good biochemical control rates after SRT. While this ana-
lysis could not prove a positive effect of dose escalation
beyond 70 Gy, it does not disprove it as these doses were
only applied to an unfavorable patient selection. The data
strongly support, however, the application of at least
70 Gy rather than 66 Gy. As a consequence of modern
treatment techniques, such doses can now be applied with
only moderate toxicity also in the salvage setting.Abbreviations
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